LONDON (Alliance News) - ReNeuron Group PLC said Friday that the GBP33 million financing package it announced in July will allow it to take all of its therapeutic programmes through Phase II clinical studies across the next three years.
In a trading statement ahead of its annual general meeting Friday, the stem-cell therapy company said that all patients in its PISCES Phase I Clinical trial have been dosed with its ReN001 stem cell therapy for stroke disability. The Data Safety Monitoring Board has supported the therapy's progression to a Phase II study. A GBP1.5 million grant from the UK Technology Strategy Board will partially fund this clinical trial.
A Phase I study for its ReN009 therapy for critical limb ischaemia has been proposed, and the company is currently in the process of completing the validation of two new manufacturing sites for the studies in Europe.
It expects, subject to final regulatory approvals, that the Phase II trial with ReN001 and the Phase I trial with ReN009 treatments to be open for patient recruitment by the end of the year. It anticipates the Phase II Trial with ReN001 to be completed by the middle of 2015, and the second half of the year for the completion of Phase II with ReN009
ReNeuron said that its ReN003 programme for the treatment of blindness-causing disease retinitis pigmentosa was continuing to plan, and that it was currently developing the protocol for an initial Phase I/II clinical trial for the treatment in the UK and US.
ReNeuron's shares were trading down 4.2% at 3.45 pence Friday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2013 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)